Investors shrug off Trump’s 200% tariff threat on pharma

by Aurelia Butler 9 July 2025, 12:22 189 Views

Client Challenge

JavaScript is disabled in your browser.

Please enable JavaScript to proceed.

A required part of this site couldn’t load. This may be due to a browser
extension, network issues, or browser settings. Please check your
connection, disable any ad blockers, or try using a different browser.

Vanguard, BlackRock deliver second-half market plays that could cushion a potential growth slowdown

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

This portal is not a newspaper as it is updated without periodicity. It cannot be considered an editorial product pursuant to law n. 62 of 7.03.2001. The author of the portal is not responsible for the content of comments to posts, the content of the linked sites. Some texts or images included in this portal are taken from the internet and, therefore, considered to be in the public domain; if their publication is violated, the copyright will be promptly communicated via e-mail. They will be immediately removed.

Investors shrug off Trump’s 200% tariff threat on pharma

Vanguard, BlackRock deliver second-half market plays that could cushion a potential growth slowdown

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

ITALIAN LANGUAGE

ENGLISH LANGUAGE